Regenerative Cell and Tissue-based Therapies for Pulmonary Arterial Hypertension

Canadian Journal of Cardiology

Volumn 30, Issue 11, 2014, Pages 1350-1360

  Foster, William S ^a,b   Suen, Colin M ^a,b   Stewart, Duncan J ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOTRANSPLANTATION; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); ENDOTHELIAL PROGENITOR CELL; EX VIVO STUDY; HUMAN; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MESENCHYMAL STEM CELL; NONHUMAN; PLURIPOTENT STEM CELL; PULMONARY HYPERTENSION; REGENERATIVE MEDICINE; REVIEW; TISSUE ENGINEERING; TISSUE SCAFFOLD; CYTOLOGY; FAMILIAL PRIMARY PULMONARY HYPERTENSION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PATHOLOGY; PROCEDURES;

CELL- AND TISSUE-BASED THERAPY; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

EID: 84908479834     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2014.08.022     Document Type: Review

References (95)

1. Simonneau G., Gatzoulis M.A., Adatia I., et al. Updated clinical classification of pulmonary hypertension. JAm Coll Cardiol 2013, 62:D34-D41.
2. Archer S.L., Weir E.K., Wilkins M.R. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010, 121:2045-2066.
3. Farber H.W., Loscalzo J. Pulmonary arterial hypertension. New Engl J Med 2004, 351:1655-1665.
4. Budhiraja R., Tuder R.M., Hassoun P.M. Endothelial dysfunction in pulmonary hypertension. Circulation 2004, 109:159-165.
5. Sakao S., Tatsumi K., Voelkel N.F. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res 2009, 10:95.
6. Tuder R.M., Cool C.D., Geraci M.W., et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999, 159:1925-1932.
7. Giaid A., Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. New Engl J Med 1995, 333:214-221.
8. Christman B.W., McPherson C.D., Newman J.H., et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. New Engl J Med 1992, 327:70-75.
9. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 1993, 328:1732-1739.
10. Jurasz P., Courtman D., Babaie S., Stewart D.J. Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials. Pharmacol Ther 2010, 126:1-8.
11. Abe K., Toba M., Alzoubi A., et al. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010, 121:2747-2754.
12. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009, 119:2250-2294.
13. Thenappan T., Shah S.J., Rich S., et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation. Eur Respir J 2010, 35:1079-1087.
14. Wedgwood S., Dettman R.W., Black S.M. ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1058-L1067.
15. Knoepfler P.S. Deconstructing stem cell tumorigenicity: a roadmap to safe regenerative medicine. Stem Cells 2009, 27:1050-1056.
16. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
17. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
18. Shi Q., Rafii S., Wu M.H., et al. Evidence for circulating bone marrow-derived endothelial cells. Blood 1998, 92:362-367.
19. Mead L.E., Prater D., Yoder M.C., Ingram D.A. Isolation and characterization of endothelial progenitor cells from human blood. Curr Protoc Stem Cell Biol 2008, Chapter 2:Unit 2C.1.
20. Hirschi K.K., Ingram D.A., Yoder M.C. Assessing identity, phenotype, and fate of endothelial progenitor cells. Arterioscler Thromb Vasc Biol 2008, 28:1584-1595.
21. Favre J., Terborg N., Horrevoets A.J. The diverse identity of angiogenic monocytes. Eur J Clin Invest 2013, 43:100-107.
22. Ingram D.A., Caplice N.M., Yoder M.C. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. Blood 2005, 106:1525-1531.
23. Tura O., Skinner E.M., Barclay G.R., et al. Late outgrowth endothelial cells resemble mature endothelial cells and are not derived from bone marrow. Stem Cells 2013, 31:338-348.
24. Mund J.A., Estes M.L., Yoder M.C., Ingram D.A., Case J. Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells. Arterioscler Thromb Vasc Biol 2012, 32:1045-1053.
25. Yoder M.C. Defining human endothelial progenitor cells. JThromb Haemost 2009, 7(suppl 1):49-52.
26. Hur J., Yoon C.H., Kim H.S., et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004, 24:288-293.
27. Jones C.P., Rankin S.M. Bone marrow-derived stem cells and respiratory disease. Chest 2011, 140:205-211.
28. Medina R.J., O'Neill C.L., Sweeney M., et al. Molecular analysis of endothelial progenitor cell (EPC) subtypes reveals two distinct cell populations with different identities. BMC Med Genomics 2010, 3:18.
29. Yoon C.H., Hur J., Park K.W., et al. Synergistic neovascularization by mixed transplantation of early endothelial progenitor cells and late outgrowth endothelial cells: the role of angiogenic cytokines and matrix metalloproteinases. Circulation 2005, 112:1618-1627.
30. Ingram D.A., Mead L.E., Tanaka H., et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and umbilical cord blood. Blood 2004, 104:2752-2760.
31. Yoder M.C., Mead L.E., Prater D., et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109:1801-1809.
32. Suen C.M., Mei S.H., Kugathasan L., Stewart D.J. Targeted delivery of genes to endothelial cells and cell- and gene-based therapy in pulmonary vascular diseases. Compr Physiol 2013, 3:1749-1779.
33. Zhao Y.D., Courtman D.W., Deng Y., et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005, 96:442-450.
34. Ormiston M.L., Deng Y., Stewart D.J., Courtman D.W. Innate immunity in the therapeutic actions of endothelial progenitor cells in pulmonary hypertension. Am J Respir Cell Mol Biol 2010, 43:546-554.
35. Burchfield J.S., Dimmeler S. Role of paracrine factors in stem and progenitor cell-mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008, 1:4.
36. Cho H.J., Lee N., Lee J.Y., et al. Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart. JExp Med 2007, 204:3257-3269.
37. Urbich C., Aicher A., Heeschen C., et al. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. JMol Cell Cardiol 2005, 39:733-742.
38. Alphonse R.S., Vadivel A., Fung M., et al. Existence, functional impairment, and lung repair potential of endothelial colony-forming cells in oxygen-induced arrested alveolar growth. Circulation 2014, 129:2144-2157.
39. Wang X.X., Zhang F.R., Shang Y.P., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. JAm Coll Cardiol 2007, 49:1566-1571.
40. Zhu J.H., Wang X.X., Zhang F.R., et al. Safety and efficacy of autologous endothelial progenitor cells transplantation in children with idiopathic pulmonary arterial hypertension: open-label pilot study. Pediatr Transplant 2008, 12:650-655.
41. Mirsky R., Jahn S., Koskenvuo J.W., et al. Treatment of pulmonary arterial hypertension with circulating angiogenic cells. Am J Physiol Lung Cell Mol Physiol 2011, 301:L12-L19.
42. Campbell A.I., Zhao Y., Sandhu R., Stewart D.J. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001, 104:2242-2248.
43. Zhao Y.D., Courtman D.W., Ng D.S., et al. Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am J Respir Cell Mol Biol 2006, 35:182-189.
44. Zhao Y.D., Campbell A.I., Robb M., Ng D., Stewart D.J. Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 2003, 92:984-991.
45. Nagaya N., Kangawa K., Kanda M., et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 2003, 108:889-895.
46. Zhao Q., Liu Z., Wang Z., et al. Effect of prepro-calcitonin gene-related peptide-expressing endothelial progenitor cells on pulmonary hypertension. Ann Thorac Surg 2007, 84:544-552.
47. Campbell A.I., Kuliszewski M.A., Stewart D.J. Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 1999, 21:567-575.
48. Wei L., Zhu W., Xia L., et al. Therapeutic effect of eNOS-transfected endothelial progenitor cells on hemodynamic pulmonary arterial hypertension. Hypertens Res 2013, 36:414-421.
49. Lalu M.M., McIntyre L., Pugliese C., et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One 2012, 7:e47559.
50. Dominici M., Le Blanc K., Mueller I., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
51. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
52. da Silva Meirelles L., Caplan A.I., Nardi N.B. In search of the invivo identity of mesenchymal stem cells. Stem Cells 2008, 26:2287-2299.
53. Lama V.N., Smith L., Badri L., et al. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. JClin Invest 2007, 117:989-996.
54. da Silva Meirelles L., Chagastelles P.C., Nardi N.B. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. JCell Sci 2006, 119:2204-2213.
55. Ranganath S.H., Levy O., Inamdar M.S., Karp J.M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012, 10:244-258.
56. Baber S.R., Deng W., Master R.G., et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 2007, 292:H1120-H1128.
57. Leiker M., Suzuki G., Iyer V.S., Canty J.M., Lee T. Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant 2008, 17:911-922.
58. Krampera M., Galipeau J., Shi Y., et al. Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 2013, 15:1054-1061.
59. Ren G., Zhang L., Zhao X., et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2:141-150.
60. Ryan J.M., Barry F.P., Murphy J.M., Mahon B.P. Mesenchymal stem cells avoid allogeneic rejection. JInflamm (Lond) 2005, 2:8.
61. Kanki-Horimoto S., Horimoto H., Mieno S., et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006, 114:I181-I185.
62. Umar S., de Visser Y.P., Steendijk P., et al. Allogenic stem cell therapy improves right ventricular function by improving lung pathology in rats with pulmonary hypertension. Am J Physiol Heart Circ Physiol 2009, 297:H1606-H1616.
63. Luan Y., Zhang Z.H., Wei D.E., et al. Implantation of mesenchymal stem cells improves right ventricular impairments caused by experimental pulmonary hypertension. Am J Med Sci 2012, 343:402-406.
64. Lee C., Mitsialis S.A., Aslam M., et al. Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension. Circulation 2012, 126:2601-2611.
65. Valadi H., Ekstrom K., Bossios A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
66. Vlassov A.V., Magdaleno S., Setterquist R., Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta 2012, 1820:940-948.
67. Takemiya K., Kai H., Yasukawa H., et al. Mesenchymal stem cell-based prostacyclin synthase gene therapy for pulmonary hypertension rats. Basic Res Cardiol 2010, 105:409-417.
68. Liang O.D., Mitsialis S.A., Chang M.S., et al. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. Stem Cells 2011, 29:99-107.
69. Alexopoulou L., Holt A.C., Medzhitov R., Flavell R.A. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001, 413:732-738.
70. Waterman R.S., Henkle S.L., Betancourt A.M. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One 2012, 7:e45590.
71. Zhao X., Liu D., Gong W., et al. The toll-like receptor 3 ligand, poly(I: C), improves immunosuppressive function and therapeutic effect of mesenchymal stem cells on sepsis via inhibiting MiR-143. Stem Cells 2014, 32:521-533.
72. Rosova I., Dao M., Capoccia B., Link D., Nolta J.A. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells 2008, 26:2173-2182.
73. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
74. Okita K., Ichisaka T., Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007, 448:313-317.
75. Li Z., Hu S., Ghosh Z., Han Z., Wu J.C. Functional characterization and expression profiling of human induced pluripotent stem cell- and embryonic stem cell-derived endothelial cells. Stem Cells Dev 2011, 20:1701-1710.
76. Lai W.H., Ho J.C., Chan Y.C., et al. Attenuation of hind-limb ischemia in mice with endothelial-like cells derived from different sources of human stem cells. PLoS One 2013, 8:e57876.
77. Margariti A., Winkler B., Karamariti E., et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc Natl Acad Sci U S A 2012, 109:13793-13798.
78. Rabinovitch M. Combining induced pluripotent stem cell with next generation sequencing technology to gain new insights into pathobiology and treatment of pulmonary arterial hypertension. Pulm Circ 2013, 3:153-155.
79. Adams W.J., Zhang Y., Cloutier J., et al. Functional vascular endothelium derived from human induced pluripotent stem cells. Stem Cell Reports 2013, 1:105-113.
80. Lavoie J.R., Ormiston M.L., Perez-Iratxeta C., et al. Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertension. Circulation 2014, 129:2125-2135.
81. Sirois I., Raymond M.A., Brassard N., et al. Caspase-3-dependent export of TCTP: a novel pathway for antiapoptotic intercellular communication. Cell Death Differ 2011, 18:549-562.
82. U.S. Department of Health and Human Services. Organ Procurement and Transplantation Network. Available at: . Accessed August 1,2014. http://optn.transplant.hrsa.gov.
83. Lyu D.M., Zamora M.R. Medical complications of lung transplantation. Proc Am Thorac Soc 2009, 6:101-107.
84. Wagner D.E., Bonvillain R.W., Jensen T., et al. Can stem cells be used to generate new lungs? Exvivo lung bioengineering with decellularized whole lung scaffolds. Respirology 2013, 18:895-911.
85. Ott H.C., Clippinger B., Conrad C., et al. Regeneration and orthotopic transplantation of a bioartificial lung. Nat Med 2010, 16:927-933.
86. Macchiarini P., Jungebluth P., Go T., et al. Clinical transplantation of a tissue-engineered airway. Lancet 2008, 372:2023-2030.
87. Gonfiotti A., Jaus M.O., Barale D., et al. The first tissue-engineered airway transplantation: 5-year follow-up results. Lancet 2014, 383:238-244.
88. Badylak S.F., Taylor D., Uygun K. Whole-organ tissue engineering: decellularization and recellularization of three-dimensional matrix scaffolds. Annu Rev Biomed Eng 2011, 13:27-53.
89. Dunsmore S.E., Rannels D.E. Extracellular matrix biology in the lung. Am J Physiol 1996, 270:L3-27.
90. Daly A.B., Wallis J.M., Borg Z.D., et al. Initial binding and recellularization of decellularized mouse lung scaffolds with bone marrow-derived mesenchymal stromal cells. Tissue Eng Part A 2012, 18:1-16.
91. Ghaedi M., Calle E.A., Mendez J.J., et al. Human iPS cell-derived alveolar epithelium repopulates lung extracellular matrix. JClin Invest 2013, 123:4950-4962.
92. Petersen T.H., Calle E.A., Zhao L., et al. Tissue-engineered lungs for invivo implantation. Science 2010, 329:538-541.
93. Scarritt M.E., Bonvillain R.W., Burkett B.J., et al. Hypertensive rat lungs retain hallmarks of vascular disease upon decellularization but support the growth of mesenchymal stem cells. Tissue Eng Part A 2014, 20:1426-1443.
94. Song J.J., Kim S.S., Liu Z., et al. Enhanced invivo function of bioartificial lungs in rats. Ann Thorac Surg 2011, 92:998-1005. [discussion: 6].
95. Gilpin S.E., Guyette J.P., Gonzalez G., et al. Perfusion decellularization of human and porcine lungs: bringing the matrix to clinical scale. JHeart Lung Transplant 2014, 33:298-308.